Insider Selling: Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $30,150.00 in Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $2.01, for a total transaction of $30,150.00. Following the completion of the transaction, the insider owned 3,375,664 shares in the company, valued at approximately $6,785,084.64. This trade represents a 0.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Trading Down 6.0%

Shares of DYAI stock opened at $1.00 on Thursday. Dyadic International Inc. has a 12-month low of $0.65 and a 12-month high of $1.35. The company has a market capitalization of $36.33 million, a PE ratio of -4.33 and a beta of 1.15. The firm has a 50 day moving average price of $0.78 and a two-hundred day moving average price of $0.83. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, analysts predict that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.00.

Institutional Trading of Dyadic International

Institutional investors have recently bought and sold shares of the business. Apis Capital Advisors LLC bought a new stake in Dyadic International in the 3rd quarter valued at about $1,817,000. Geode Capital Management LLC increased its holdings in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International in the third quarter valued at approximately $190,000. Marathon Capital Management raised its position in shares of Dyadic International by 142.9% in the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the period. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.